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Abstract
Osteoporosis, a disease resulting in an increased risk of fracture due to compromised bone, affects 1 in 3 postmenopausal 
women. Discontinuities in the microarchitecture of bone, such as trabeculae, are seen in postmenopausal osteoporosis. This 
study aimed to evaluate how sleep deprivation affects the distal femur trabecular thickness of estrogen-deficient rats treated with 
Zoledronate. 29 ovariectomized Wistar female rats were separated into 4 groups. The control group (C) was housed in standard 
housing with a 12-hour light/dark cycle and was given an intravenous injection of 0.45 mL of 0.9% saline. The Zoledronate 
group (Z) were also housed in standard conditions but given an intravenous injection of 50 ug/kg of 10% Zoledronate. The 
Sleep Deprived group (SD) were given an intravenous saline injection, but were housed in chambers that did not permit sleep 
for 18 hours, then moved to standard chambers that permitted 6 hours of sleep daily. The Sleep-Deprived Zoledronate group 
(SDZ) was housed the same as the SD group, but was given an intravenous injection of Zoledronate. After 5 weeks, tibiae and 
femora were harvested and stored at -80°C until high-resolution micro-CT was done. SDZ had improved distal femur trabecular 
thickness compared to C (75.5 microns and 67 microns, respectively; p=0.0001). Multi-factor ANOVA revealed a significant 
interaction between Zoledronate and sleep deprivation (p=0.0078). More research is needed to determine how this interaction 
impacts executive women who often suffer from sleep deprivation and demanding professions.
Keywords: Bone; Executive women; Osteoporosis; 
Postmenopausal zoledronate; Sleep deprivation
Introduction
Osteoporosis is a skeletal disorder that compromises 
the strength of bone, leading to increased risk for fracture [1]. 
Osteoporosis can be detrimental to physical and mental health, yet 
it is not a popular topic despite being identified as one of the most 
significant diseases affecting human health. Women are more prone 
to osteoporosis than men. One in three women over the age of 50 
will experience a fracture due to osteoporosis [2]. The mechanism 
of how osteoporosis affects bone is understood, but there are many 
factors, including menopause, that may influence the progression 
of the disease. Bone is a metabolically active tissue with 
osteoblasts creating inorganic substance and osteoclasts breaking 
down the inorganic substance when minerals, such as calcium, 
are needed. The inorganic substance makes up 60 percent of bone 
and gives it its strength and rigidity [3]. Typically, osteoblast and 
osteoclast activity is about equal, but osteoporosis is characterized 
by overactive osteoclastic activity, decreased osteoblastic activity, 
or a significant decrease in the activity of both [4]. 
Bones consist of a dense portion known as cortical bone 
and an internal network of filaments known as trabecular bone 
[2]. The progressive architectural deterioration of trabecular bone 
can be seen by the disconnection of trabeculae due to loss of bone 
mineral content. Depletion of calcium in the trabeculae is one of 
the abnormalities in bone that leads to fracture in osteoporosis [2]. 
Trabecular bone is 3-4 times more metabolically active than cortical 
bone making it a good indicator of disease as it responds quicker 
than cortical bone [5]. This study focuses on trabecular thickness 
because recent research suggests that the quality of bone may be a 
better indicator of bone health [2]. While elderly men and women 
are at a greater risk of developing osteoporosis, postmenopausal 
women have the highest age-adjusted risk of fracture [1]. It is 
understood that estrogens play a vital role in bone protection by 
silencing osteoclasts [6]. When a woman goes through menopause 
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and estrogen is no longer regularly produced, osteoclast activity 
increases, and bone mineral density and bone strength decrease 
[1,6]. There is no cure for postmenopausal osteoporosis, but 
research is beginning to look at different medications and lifestyle 
changes that could influence the disease by preventing bone 
resorption.
As the population ages and retires later in life, concern 
for health implications due to inadequate sleep are viable [7-9]. 
In 1910 average sleep duration was approximately 9 hours, but 
currently, the average sleep duration among adults is 7.5 hours 
[8]. With more women working now than ever before, concern 
for sleep duration and sleep disturbances have become more 
responsible for the health maintenance area of research [9,10]. 
While data has not indefinitely suggested the relationship between 
sleep and osteoporosis, research suggests that lack of sleep 
leads to decreased bone mineral density and strength [11,12], 
particularly for postmenopausal women [10]. Another area of 
study for postmenopausal osteoporosis is the pharmaceutical 
role of bisphosphonates [5]. Bisphosphonates are used to slow 
the progression of bone resorption by binding to hydroxyapatite 
crystals, which inhibits the dissolution of the calcium phosphate 
[13,14]. This binding mechanism to hydroxyapatite crystals of 
bone leads to slower recruitment of osteoclasts and eventually 
apoptosis [13]. There are many different kinds of bisphosphonates, 
but Zoledronate is considered to be one of the most potent [13]. 
Zoledronate is a nitrogen-based bisphosphonate which allows for 
stronger binding to bone [14]. Zoledronate has been shown to 
improve the trabeculae in rats, and is generally well-tolerated in 
clinical trials by humans, making it a promising choice as a treatment 
for postmenopausal osteoporosis [13,15]. An annual intravenous 
infusion of Zoledronate in clinical practice has been preferred 
by patients compared to other bisphosphonates [16]. While it is 
well understood how Zoledronate affects osteoclasts, there also 
has been some research on how Zoledronate affects osteoblasts. 
One study found that, for postmenopausal osteoporosis, smaller 
doses such as 0.5 mg/kg body weight is ideal because it inhibits 
osteoclasts without interfering in osteoblast activity [17]. Lifestyle 
changes and pharmaceuticals have been studied well individually 
in postmenopausal osteoporosis, but there is limited research that 
predicates the implications of both.
Materials and Methods
Wistar female rats (n=29), who had a mean weight of 
341g and were 8-months old, were ovariectomized by Charles 
River Laboratories, Boston, MA, prior to the reception. This was 
done to simulate an estrogen-deficient environment comparable 
to menopause in humans. There are different strategies that 
manipulate the hormonal milieu that simulate a post-menopausal 
state in the animals. However, we felt that to best mimic the 
cessation of ovarian function, the surgical removal of the ovaries 
was the best and least complicating hormonally of the procedures. 
The rats had a 1-week adjustment period where they were placed 
in their individual housing cages and were provided with Purina 
rat chow and water ad libitum before the experimental period 
began. A 12-hour light/dark cycle was kept during this week 
where lights came on at 7:00 and turned off at 19:00. After the 
week, the rats were then randomly assigned into different groups 
(Table 1), including a control group (C, n=5), a sleep-deprived 
group (SD, n=8), a group treated with Zoledronate (Z, n=8), 
and a sleep-deprived group who also received Zoledronate for 
treatment (SDZ, n=8). The University Institutional Review Board 
(IRB) approved the protocol and methodology for this study. All 
animal procedures, including housing, food provision, anesthesia, 
surgeries, and sacrifice, were in accordance with the 2015 IACUC 
guidelines.
Group Number of Rats Injection Given Sleep Deprived
C 5 0.45 mL 0.9% saline No
SD 8 0.45 mL 0.9% saline Yes
Z 8 50 ug/kg Zoledronate No
SDZ 8 50 ug/kg Zoledronate Yes
C= Control; Z= Zoledronate; SD= Sleep-deprived; SDZ= Sleep-
Deprived Zoledronate
Table 1: Group classifications.
The groups that received Zoledronate, including the Z and 
the SDZ groups, were given an intravenous injection through the 
tail vein of 50 ug/kg of body weight. Only one injection was needed 
for the five-week study due to the potency of Zoledronate and its 
ability to bind to the hydroxyapatite crystals of bone. The C and SD 
groups were given a one-time intravenous injection of 0.45mL of 
0.9% saline to experience the same stress of injection as the Z and 
SDZ had. After the injection, the 5-week experiment was started. 
During the five-week period, sleep deprivation was simulated 
by the Modified Multiple Platform Method (MMPM) [18]. We 
modified rectangular acrylic fish tanks (144cmx44cmx44cm); one 
for the SD group and one for the SDZ group, that were fitted with 
14 circular platforms that had a diameter of 6.5cm (Figure 1). The 
platforms were 10cm away from each other. Each tank was filled 
with room-temperature water until the water reached 1cm below 
the top of the platforms (Figure 1). Purina rat chow and drinking 
water were available in the tanks at all times. The food and fresh 
water were placed in accessible containers positioned at the top of 
the tanks and away from the standing water and platforms. These 
tanks allowed the rats to move around, but if they fell asleep, they 
would fall into the water and be woken up. Therefore, these rats 
were unable to maintain a normal sleep cycle. The SD and SDZ 
rats participated in 1 of 3 different sleep cycles each day (Table 2). 
The sleep cycle was assigned using a random number generator. 
Each day at 14:00, the rats were moved into the MMPM tanks. 
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Then between 07:00 and 09:00, they were moved to a tank with wood chip bedding, food and water, and that allowed sleep in the 
darkness. This provided the rats with 5-7 hours of sleep per day, depending on the cycle permitted (Table 3). The C and Z groups were 
housed under standard conditions and permitted 12 hours of light/dark. 
Figure 1: Modified multiple platform tank.
Sleep Cycle Start Time End Time Time Awake (hrs) Time Allowed for Sleep (hrs)
SC1 14:00 9:00 19 5
SC2 14:00 8:00 18 6
SC3 14:00 7:00 17 7
A random number generator would select one of the three sleep cycles listed above, daily. The rats would be placed in the MMP tank during the 
wake time, then they would be moved to a standard chamber for sleeping.
Table 2: Sleep cycles.
Day Time Awake (hr.) Time Asleep (hr.) Sleep Cycle
1 17 7 3
2 18 6 2
3 19 5 1
4 17 7 3
5 18 6 2
6 19 5 1
7 18 6 2
8 17 7 3
9 19 5 1
10 17 7 3
11 17 7 3
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12 17 7 3
13 19 5 1
14 17 7 3
15 17 7 3
16 17 7 3
17 17 7 3
18 19 5 1
19 19 5 1
20 19 5 1
21 18 6 2
22 19 5 1
23 18 6 2
24 19 5 1
25 18 6 2
26 19 5 1
27 19 5 1
28 17 7 3
29 19 5 1
30 18 6 2
31 18 6 2
32 18 6 2
33 18 6 2
34 17 7 3
35 17 7 3
Amount of sleep permitted as indicated by the sleep cycle. Sleep cycle was determined by a random number generator. The amount of wake time 
was spent in the MMP tank.
Table 3: Daily Sleep/Wake Times.
At the end of 5 weeks, blood and tissue samples were collected and frozen prior to death. The rats were sedated with 0.001 mL/g 
of ketamine/atropine/xylazine cocktail. Following sedation, all animals were decapitated and exsanguinated. Blood was obtained and 
centrifuged at 14,000 RPM for 5 minutes at 5°C and frozen at -80°C for studies not reported in this paper. Femora and tibiae were 
harvested, wrapped in saline-soaked gauze, and frozen at -80°C. The right tibiae and femora of each rat were shipped to Novartis 
Institute for Biomedical Research. Ex vivo DEXA scans ex vivo high-resolution micro-Computed Tomography (micro-CT) and 
peripheral Quantitative computed tomography (pQCT) of the distal and midshaft femur (Figure 2). The scans and data were then sent 
to Chapman University for analysis. This report is limited to the femora data, which was statistically analyzed with the use of multiple 
comparisons tests and ANOVA in RStudio.
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Figure 2: Depiction of Location of micro-CT and pQCT of the 
Distal Femur Ex vivo location of the micro-CT and pQCT of the 
rat’s distal femur.
Results 
Data from the micro-CT suggested an increase in distal 
femur trabecular thickness between the C and SDZ groups (67, 
75.5 microns, respectively; p=0.0001) (Table 4). Additionally, 
sleep deprivation seemed to improve distal femur trabecular 
thickness between the Z and SDZ groups (68.375, 75.5 microns, 
respectively, p=0.00007). Because the sleep deprivation seemed to 
improve distal femur trabecular thickness, a multi-factor ANOVA 
was conducted and revealed a significant interaction between the 
treatment and the amount of sleep the rats received (p=0.0078) 
(Figure 3). 
Figure 3: Interaction plot between Treatment and Housing.
Estimates from an ANOVA model with treatments as main 
effect and an interaction term as covariates (p=0.0078, R2 = 0.612). 
Group Average Distal Femur Trabecular Thickness (microns)
Control (C) 67 ± 0.721
Zoledronate (Z) 68.375 ± 0.240
Sleep-Deprived (SD) 68.375 ± 0.188
Sleep-Deprived + 
Zoledronate (SDZ) 75.5*** ± 0.400
The average distal femur trabecular thickness of each group including 
standard error. A significant difference was determined with ANOVA 
between the Control and Sleep-Deprived Zoledronate groups. 
***P=0.0001
Table 4: Average Distal Femur Trabecular Thickness of Each 
Group.
Discussion 
It was expected that sleep deprivation would cause thinner 
trabeculae in the distal femora of ovariectomized rats and that 
treatment with Zoledronate would improve this. However, data 
suggested that the sleep-deprived groups had a greater distal 
femur trabecular thickness. Because the SDZ group had a much 
greater increase in distal femur trabecular thickness than the Z 
group, an interaction plot was created using ANOVA. The plot 
revealed a possible physiological interaction between the amount 
of sleep and the use of Zoledronate. Further studies are needed to 
determine the mechanism behind the physiological interaction, but 
results could have a profound impact on the use of Zoledronate in 
modern society where many people are getting less sleep because 
of work Demands. While the animals in this study were provided 
lab chow ad libitum, future studies should include the evaluation 
of the amount of food daily ingested.  It is widely observed that 
food intake may be modified by the stress of decreased sleep [19]. 
This could be a factor in the metabolism of bone tissue. Another 
consideration that should be addressed is the sample size of this 
study. Though there was significance between the C and SDZ 
groups, the small sample size of 32 rats may not have been robust 
enough to provide more illumination into the effects of this protocol. 
Other studies that have tested Zoledronate in ovariectomized rats 
have had at least 80 rats [20-22]. The duration of this study was 
carefully considered, with it being estimated that the relative age 
for humans during a postmenopausal period over 1 year is equal to 
11.8 days for rats [23]. Given this information, it was determined 
that a 5-week trial for the rats would be approximately a 3-year 
trial for postmenopausal women, which is a common timeline for 
bisphosphonate clinical trials. 
While the MMPM has been a commonly used technique 
for sleep deprivation in animal studies, it may have stimulated 
osteoblast activity in this study. One study that looked at the effects 
of exercise on ovariectomized rats found that the rats who were 
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forced to run each day had significantly greater bone mass especially 
in the trabecular bone [24]. In humans, this phenomenon (Wolff’s 
Law) causes improved bone quality and increased bone mineral 
content when the bone experiences greater mechanical stress over 
time [25]. In future studies, consideration should be taken of the 
type of bisphosphonate used and the timing of the injection. While 
Zoledronate is one of the most potent bisphosphonates, there 
have been recent studies that suggest diluting it with propanol or 
parathyroid hormone has been more effective than Zoledronate by 
itself [26,27]. 
Conclusion
Executive women, who often suffer from sleep deprivation, 
are a growing subclass of postmenopausal patients suffering from 
osteoporosis. This study attempted to evaluate Zoledronate as an 
intervention to reduce bone loss. While these data suggested a 
significance in the SDZ group compared to the C group, a trial of 
longer duration and greater sample size may be more illuminating. 
Rats held in the sleep deprivation tanks may have been using muscles 
which may have stimulated osteoblasts. Overall, Zoledronate may 
have a protective effect in sleep-deprived ovariectomized rats and 
suggests promise as a therapeutic intervention for postmenopausal 
executive women with osteoporosis. 
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